During the current COVID-19 pandemic, healthcare professionals are faced with multiple management issues, including resource utilization and non-availability of equipment, and potential risks of exposure for staff and other patients.

Several proposals in the United States and internationally, with the earliest experience, raise questions about the management of ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI). The Wuhan protocol for patients diagnosed with or highly suspected to have COVID-19 infection recommended thrombolytics rather than primary percutaneous coronary intervention (PCI). This has led to discussion about how to best manage patients with acute coronary syndromes in the United States, including potentially using thrombolytics as first-line management. Multiple recommendations have been or are rapidly being published, but let's see how you feel about this issue.

Clinical Topics: Acute Coronary Syndromes, COVID-19 Hub, Invasive Cardiovascular Angiography and Intervention, Noninvasive Imaging, Interventions and ACS, Interventions and Imaging, Angiography, Nuclear Imaging

Keywords: Angiography, Coronary Angiography, Coronavirus, COVID-19, Myocardial Infarction, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Pandemics, Fibrinolytic Agents, Anterior Wall Myocardial Infarction, Infections, Severe Acute Respiratory Syndrome

< Back to Listings